CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea, Neisseria gonorrhoeae (NG), and its susceptibility to ciprofloxacin, a former frontline oral antibiotic that can no longer treat resistant NG.

Near-Perfect Control of Slow-Growing Lymphoma With Low-Dose Radiotherapy

Low-dose radiotherapy for a slow-growing stomach lymphoma achieved near-perfect disease control with no severe toxicity, a small prospective study showed. After a 4 Gy dose

June 7, 2024

Pharmalittle: We’re reading about a canceled Roche trial, low VC biotech funding, and more

Top of the morning to you. Another steamy day is unfolding here at the Pharmalot campus, where the official mascots are scampering about and enjoying

August 6, 2024

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses | Psychedelic Invest

– Company speakers include Doug Drysdale, Chief Executive Officer; and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer – – Featured key opinion leaders

December 1, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.